Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bryostatin 1
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 60 for your search:
Start Over
Phase II Trial of Bryostatin 1 for Metastatic Malignant Melanoma (Summary Last Modified 11/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: UCHSC-96309, NCI-T94-0171D, T94-0171
Phase II Study of Bryostatin 1 for Advanced Melanoma (Summary Last Modified 11/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UPCC-1694, NCI-T95-0010D, T95-0010
Phase II Study of Continuous-Infusion Bryostatin 1 for Chronic Myelogenous Leukemia (Summary Last Modified 11/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCHSC-96-344, NCI-T95-0015H, T95-0015
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: NCI-2012-02239, MDA-DM-95061, NCI-T95-0035D, CDR0000064591, T95-0035, NCT00002725
Phase II Study of BRYO for Metastatic or Unresectable Renal Cell Carcinoma (Summary Last Modified 10/00)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-DM-95166, NCI-T95-0085H, T95-0085
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065272, P30CA022453, WSU-C-1257, WSU-D-1257, NCI-T95-0062D, T95-0062, NCT00002907
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065273, P30CA022453, WSU-C-1256, WSU-D-1256, NCI-T95-0058D, T95-0058, NCT00002908
Phase II Open Label Study of Bryostatin in Patients with Low Grade Non-Hodgkin's Lymphoma (Summary Last Modified 01/2000)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CRC-PHASE-II-PH2/031
Phase II Trial of Bryostatin 1 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas (Summary Last Modified 08/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-NCNSC-96213, NABTC-NCNSC-96213, NCI-T96-0080, T96-0080
Phase II Study of Tretinoin and Bryostatin 1 in Patients with Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes (Summary Last Modified 03/2001)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-96278, NCI-T96-0112, T96-0112
Phase II Study of Bryostatin 1 in Advanced Malignant Melanoma (Summary Last Modified 09/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND104, NCI-T96-0089, T96-0089, IND104
Phase II Study of Bryostatin in Patients with Previously Untreated, Recurrent, or Refractory AIDS-Related B Cell Lymphomas (Summary Last Modified 01/2000)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSGCC-9711, NCI-T97-0037, T97-0037
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065975, P30CA022453, WSU-D-1468, NCI-T97-0047, T97-0047, NCT00003171
Phase II Study of Bryostatin 1 in Patients with Advanced and Recurrent Bone or Soft Tissue Sarcoma (Summary Last Modified 01/99)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-9070, NCI-T97-0075, T97-0075
Phase II Study of Bryostatin 1 in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 03/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-9069, NCI-T97-0076, T97-0076
Phase II Study of Bryostatin 1 in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 04/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-9801, NCI-T-97-0070, T97-0070
Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 97-0751.cc, UCHSC-97751, NCI-T97-0063, T97-0063, NCT00003205
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000066081, P30CA022453, WSU-D-1457, NCI-T97-0065, T97-0065, NCT00003220
Phase II Randomized Study of Bryostatin 1 in Patients with Persistent or Recurrent Squamous Cell Carcinoma of the Cervix
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-127N
Phase II Randomized Study of Bryostatin 1 in Patients With Unresectable Metastatic Melanoma (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: MDA-DM-97253, NCI-T97-0093, T97-0093
Phase II Randomized Study of Bryostatin 1 Followed by Combination Chemotherapy with Vincristine, Doxorubicin, and Dexamethasone (VAD) for Multiple Myeloma (Summary Last Modified 10/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-98020607, NCI-T97-0074, T97-0074
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067128, P30CA022453, WSU-C-1902, NCI-T97-0120, T97-0120, NCT00003936
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02303, FCCC-99012, NCI-T99-0002, CDR0000067169, T99-0002, NCT00003968
Start Over